))
Expanded analysis of their data from their first clinical trial of troriluzole in SCA patients.
Manage episode 310696178 series 3068946
Content provided by Dana Mauro. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dana Mauro or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
This Podcast from the annual NAF Meeting in Las Vegas, March, 2019 features Gil L’Italien, PhD, Head of GHEOR and Epidemiology and Melissa Wolfe Beiner, MD, Director of Research and Development and Ataxia Medical Lead, both from Biohaven Pharmaceuticals. They are with us to highlight some important and encouraging new data from an expanded analysis of their data from their first clinical trial of troriluzole in SCA patients. This clinical trial was the first registrational trial in SCA patients in the United States. In addition, they will discuss a new clinical trial, which is beginning this month at sites across the country, studying troriluzole in SCA patients with a new study design, optimized from data from their initial study, as well as data from the US Natural History Study. This work reflects a collaboration between Biohaven and numerous experts in the ataxia field across the country.
55 episodes
Share
